PEPTIDE CORPUS

Metabolic & Weight Management

Tirzepatide

Space-filling model of Tirzepatide

A dual incretin signal for weight and glycemic-control research.

Last updated

Studied forWeight loss · Glycemic control · OSA improvement context
Evidence on fileFDA-approved · 4 citations not yet graded

Mechanism

Combines GLP-1 satiety/gastric-delay signaling with GIP insulinotropic effects.

Regulatory status

Approved by the FDA. Marketed as MOUNJARO, MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND KWIKPEN. Earliest approval 2022-05-13. Application NDA215866, NDA217806.

An approval grades as rung 1 on this site, because 21 CFR 314.126 requires adequate and well-controlled human investigations and one cannot be granted without them. It covers specific indications and doses, though, and does not transfer to other uses of the same molecule.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

  • Weight loss
  • Glycemic control
  • OSA improvement context

Dosing on file unverified

0.5-15 mg weekly, cycled 12–72 weeks

Reported doseVolumeDraw
Low — 0.5 mg0.2 mL20 units
High — 15 mg6 mL600 units

What that assumes. Assumes 5 mg in 2 mL (2500 mcg/mL) drawn on a U-100 barrel — the preset on this record, not a recommendation and not the only way to mix it. Change the vial mass, the diluent or the barrel and every number in this table changes. Run your own.

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Reconstitution

VialDiluentConcentrationTypical doseDraw
5 mg2 mL2500 mcg/mL500 mcg20 units

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Reported adverse effects

  • Nausea

    Very common (>10%)onset: Dose escalationreported reversible

  • Diarrhea

    Common (1-10%)onset: First weeksreported reversible

  • Decreased appetite

    Very common (>10%)onset: Ongoing — intended effectreported reversible

  • Vomiting

    Common (1-10%)onset: Dose escalationreported reversible

Literature on file 5

Not graded

4 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Identity

PubChem CID 156588324 computed 3D conformer Space-filling 3D model of Tirzepatide, carbon grey, nitrogen blue, oxygen red
Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is one computed low-energy pose, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.
Skeletal formulathe canonical depiction
2D chemical structure of Tirzepatide

Drawn by PubChem from CID 156588324, the identifier on this record.

Molecular weight
4813
Molecular formula
C225H348N48O68
CAS number
2023788-19-2
PubChem CID
156588324; 168009818
UniProt
P43220 & P48546 (Targets)
ChEMBL
CHEMBL4297839
InChI key
AAPYRSPHYSKGIS-MCNPHUAVSA-N
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
InChI
InChI=1S/C225H348N48O68/c1-23-126(10)183(214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(64-50-52-88-226)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-173(288)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-174(289)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301)264-198(311)146(65-51-53-89-231-170(285)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-172(287)243-150(221(334)335)82-86-171(286)232-90-96-338-98-100-340-121-176(291)233-91-97-339-99-101-341-122-181(299)300)246-202(315)157(109-179(295)296)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-180(297)298)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-175(290)114-237-193(306)147(83-87-178(293)294)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,285)(H,232,286)(H,233,291)(H,235,288)(H,236,302)(H,237,306)(H,238,307)(H,239,289)(H,240,308)(H,241,326)(H,242,327)(H,243,287)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,290)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1

Classified as

Incretin Signalingpathway
Almost every compound sold as a GLP-1 acts somewhere on this pathway, and the real differences between them, one receptor or two, how long they last, how they are cleared, sit here rather than in the trade name.
Glucose Homeostasispathway
The readings a record may cite cover different windows: a fasting glucose is one moment, HbA1c reflects roughly the previous three months, a continuous monitor's average is neither. Comparing across them is a common error.
Subcutaneousroute
This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

  • Tirzepatide

Caveat on these identifiers

P43220 is the GLP-1 RECEPTOR, not the drug itself. P48546 is the GIP RECEPTOR, not the drug itself. PubChem record exists but is untitled; formula matches tirzepatide (CID 156588324).

Notes unverified prose

FDA-approved; SURMOUNT trials; SURMOUNT-MAINTAIN; PMID: 40353578; SURMOUNT-OSA; PMID: 39378016

Not on file 1

1 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.

Listed prices 2

What 2 shops we track listed for Tirzepatide, read from their own public catalogues on 2026-08-12. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Listed in CAD
VendorSizePricePer mg
Panda Peptide 10 mg $56.99 CAD $5.70/mg
Peptide Supply Online size not listed $200.00 CAD $220.00 CAD

Prices are the vendor's own listing, reproduced with the date we read it — never converted between currencies, and compared per milligram only where the vendor states the vial size.

Share this record

Share card for Tirzepatide: structure, evidence rung and sources on file
www.peptidecorpus.com/peptides/tirzepatide